Chinenye C. Azoba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chinenye C. Azoba has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Areej El-Jawahri
Massachusetts General Hospital, Boston, MA
2 shared publications - Carolyn L. Qian
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
2 shared publications - Jennifer S. Temel
Mass General Brigham (MGB) Cancer Institute, Mass General Brigham , Boston, MA
2 shared publications - Joseph Andrew Greer
Massachusetts General Hospital, Boston, USA
2 shared publications - Ryan David Nipp
Section of Hematology & Oncology, Department of Medicine, University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, OK
2 shared publications Alec C. Kimmelman
Department of Radiation Oncology, Perlmutter Cancer Center NYU Langone Medical Center, New York, NY
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (1) , e2400534
Overcoming Logistical Barriers to Conducting Collaborative Clinical Research Between a High-Income Country and a Low- and Middle-Income Country
PURPOSE: Building equitable research collaborations between high-income countries (HICs) and low- and middle-income countries (LMICs) requires effective coordination among international ethical review committees, which is often logistically challenging. This case report presents the insights gained when acquiring ethical approval for a cervical cancer research program conducted jointly by the University of Pennsylvania and the University of Botswana. METHODS: We conducted a descriptive case study of the Ipabalele project, a 6-year HIC-LMIC partnership involving three complex research protocols that required approvals by multiple distinct ethical bodies. We analyzed various challenges affecting review procedures, timelines, and staffing. We then documented strategies employed in Ipabalele and other global initiatives to strengthen ethical review processes and build research capacity in LMICs. RESULTS: In Ipabalele, ethical approvals were initially delayed by 2 years because of fragmented review processes with variable timelines and conflicting recommendations. Innovations to the process included centralizing institutional review board oversight within Botswana, implementing joint virtual meetings among review bodies, enhancing digital infrastructure, and streamlining research staffing and communication. CONCLUSION: By providing practical strategies, this study highlights how empowered local leadership, centralized review processes, joint review mechanisms, and intentional capacity building can overcome logistical barriers in multinational ethical review.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (1) , e2400534
Open AccessOvercoming Logistical Barriers to Conducting Collaborative Clinical Research Between a High-Income Country and a Low- and Middle-Income Country
PURPOSE: Building equitable research collaborations between high-income countries (HICs) and low- and middle-income countries (LMICs) requires effective coordination among international ethical review committees, which is often logistically challenging. This case report presents the insights gained when acquiring ethical approval for a cervical cancer research program conducted jointly by the University of Pennsylvania and the University of Botswana. METHODS: We conducted a descriptive case study of the Ipabalele project, a 6-year HIC-LMIC partnership involving three complex research protocols that required approvals by multiple distinct ethical bodies. We analyzed various challenges affecting review procedures, timelines, and staffing. We then documented strategies employed in Ipabalele and other global initiatives to strengthen ethical review processes and build research capacity in LMICs. RESULTS: In Ipabalele, ethical approvals were initially delayed by 2 years because of fragmented review processes with variable timelines and conflicting recommendations. Innovations to the process included centralizing institutional review board oversight within Botswana, implementing joint virtual meetings among review bodies, enhancing digital infrastructure, and streamlining research staffing and communication. CONCLUSION: By providing practical strategies, this study highlights how empowered local leadership, centralized review processes, joint review mechanisms, and intentional capacity building can overcome logistical barriers in multinational ethical review.
- 1 October 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (28_suppl) , 308
Transparency and representation in clinical research utilizing artificial intelligence in oncology: A scoping review.
308 Background: Artificial intelligence (AI) has significant potential to improve health outcomes in oncology. However, lack of demographic representation in data sets used to train and test these models can lead to model bias and potential disparities. We sought to assess transparency in reporting and representation of race, sex, and age data in published clinical studies utilizing AI in oncology. Materials and Methods: In this scoping review, we used PubMed to search for peer-reviewed research articles published between 2016 and 2021 with the query type “(“deep learning” or “machine learning” or “neural network” or “artificial intelligence”) and (“neoplas$” or “cancer$” or “tumor$” or “tumour$”).” We included clinical trials and original research studies and excluded reviews and meta-analyses. Oncology-related studies that described data sets used in training or validation of the AI models were eligible. Three investigators reviewed eligible studies to collect data regarding public reporting of patient demographics, including age, sex at birth, and race. We used descriptive statistics to analyze these data across studies. Results: Out of 220 total studies, 118 were eligible and 47 had at least one described training or validation data set. Of these, 69 studies (58%) reported age data for patients included in training or validation sets, while 60 studies (51%) reported sex and 6 studies (5%) reported race. Across studies, age ranged from 16 days-96 years. For studies that reported mean age, the overall mean was 57.8+/- 10.8 years. 48.5% of patients included in studies with reported sex were male, and 51.5% were female. 38 studies (63.3%) that reported sex included a majority of males, and 22 studies (36.7%) used a majority of females. From the 6 studies that reported race, 70.7%-93.4% of individuals were White. Only 3 studies (2.5%) reported racial demographic data with more than two categories (i.e. “White” vs. “non-White” or “White” vs. “Black”). Conclusions: In this scoping review of published studies in oncology using AI models, we found that a minority of studies reported complete demographic data of training and validation sets. In particular, studies rarely reported race, and those that did had few non-White patients. Increased transparency regarding demographic data of patients included in data sets for creation of AI models is essential to ensure fair and unbiased clinical integration of AI.
- 1 October 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (28_suppl) , 308
Transparency and representation in clinical research utilizing artificial intelligence in oncology: A scoping review.
308 Background: Artificial intelligence (AI) has significant potential to improve health outcomes in oncology. However, lack of demographic representation in data sets used to train and test these models can lead to model bias and potential disparities. We sought to assess transparency in reporting and representation of race, sex, and age data in published clinical studies utilizing AI in oncology. Materials and Methods: In this scoping review, we used PubMed to search for peer-reviewed research articles published between 2016 and 2021 with the query type “(“deep learning” or “machine learning” or “neural network” or “artificial intelligence”) and (“neoplas$” or “cancer$” or “tumor$” or “tumour$”).” We included clinical trials and original research studies and excluded reviews and meta-analyses. Oncology-related studies that described data sets used in training or validation of the AI models were eligible. Three investigators reviewed eligible studies to collect data regarding public reporting of patient demographics, including age, sex at birth, and race. We used descriptive statistics to analyze these data across studies. Results: Out of 220 total studies, 118 were eligible and 47 had at least one described training or validation data set. Of these, 69 studies (58%) reported age data for patients included in training or validation sets, while 60 studies (51%) reported sex and 6 studies (5%) reported race. Across studies, age ranged from 16 days-96 years. For studies that reported mean age, the overall mean was 57.8+/- 10.8 years. 48.5% of patients included in studies with reported sex were male, and 51.5% were female. 38 studies (63.3%) that reported sex included a majority of males, and 22 studies (36.7%) used a majority of females. From the 6 studies that reported race, 70.7%-93.4% of individuals were White. Only 3 studies (2.5%) reported racial demographic data with more than two categories (i.e. “White” vs. “non-White” or “White” vs. “Black”). Conclusions: In this scoping review of published studies in oncology using AI models, we found that a minority of studies reported complete demographic data of training and validation sets. In particular, studies rarely reported race, and those that did had few non-White patients. Increased transparency regarding demographic data of patients included in data sets for creation of AI models is essential to ensure fair and unbiased clinical integration of AI.
- 1 October 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (10) , e1587-e1593
Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer
PURPOSE: We sought to determine the feasibility of delivering a Supportive Oncology Care at Home intervention among patients with pancreatic cancer. METHODS: We prospectively enrolled patients with pancreatic cancer from a parent trial of neoadjuvant fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX). The intervention entailed (1) remote monitoring of patient-reported symptoms, vital signs, and body weight; (2) a hospital-at-home care model; and (3) structured communication with the oncology team. We defined the intervention as feasible if ≥ 60% of patients enrolled in the study and ≥ 60% completed the daily assessments within the first 2-weeks of enrollment. We determined rates of treatment delays, urgent clinic visits, emergency department visits, and hospitalizations among those who did (n = 20) and did not (n = 24) receive Supportive Oncology Care at Home from the parent trial. RESULTS: From January 2019 to September 2020, we enrolled 80.8% (21/26) of potentially eligible patients. One patient became ineligible following consent because of moving out of state, resulting in 20 participants (median age = 67 years). In the first 2 weeks of enrollment, 65.0% of participants completed all daily assessments. Overall, patients reported 96.1% of daily symptoms, 96.1% of daily vital signs, and 92.5% of weekly body weights. Patients receiving the intervention had lower rates of treatment delays (55.0% v 75.0%), urgent clinic visits (10.0% v 25.0%), and emergency department visits/hospitalizations (45.0% v 62.5%) compared with those not receiving the intervention from the same parent trial. CONCLUSION: Findings demonstrate the feasibility and acceptability of a Supportive Oncology Care at Home intervention. Future work will investigate the efficacy of this intervention for decreasing health care use and improving patient outcomes.
- 1 October 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (10) , e1587-e1593
Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer
PURPOSE: We sought to determine the feasibility of delivering a Supportive Oncology Care at Home intervention among patients with pancreatic cancer. METHODS: We prospectively enrolled patients with pancreatic cancer from a parent trial of neoadjuvant fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX). The intervention entailed (1) remote monitoring of patient-reported symptoms, vital signs, and body weight; (2) a hospital-at-home care model; and (3) structured communication with the oncology team. We defined the intervention as feasible if ≥ 60% of patients enrolled in the study and ≥ 60% completed the daily assessments within the first 2-weeks of enrollment. We determined rates of treatment delays, urgent clinic visits, emergency department visits, and hospitalizations among those who did (n = 20) and did not (n = 24) receive Supportive Oncology Care at Home from the parent trial. RESULTS: From January 2019 to September 2020, we enrolled 80.8% (21/26) of potentially eligible patients. One patient became ineligible following consent because of moving out of state, resulting in 20 participants (median age = 67 years). In the first 2 weeks of enrollment, 65.0% of participants completed all daily assessments. Overall, patients reported 96.1% of daily symptoms, 96.1% of daily vital signs, and 92.5% of weekly body weights. Patients receiving the intervention had lower rates of treatment delays (55.0% v 75.0%), urgent clinic visits (10.0% v 25.0%), and emergency department visits/hospitalizations (45.0% v 62.5%) compared with those not receiving the intervention from the same parent trial. CONCLUSION: Findings demonstrate the feasibility and acceptability of a Supportive Oncology Care at Home intervention. Future work will investigate the efficacy of this intervention for decreasing health care use and improving patient outcomes.
- 1 March 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (3) , e313-e324
Communicating the Information Needed for Treatment Decision Making Among Patients With Pancreatic Cancer Receiving Preoperative Therapy
PURPOSE: Preoperative therapy for pancreatic cancer represents a new treatment option with the potential to improve outcomes for patients, yet with complex risks. By not discussing the potential risks and benefits of new treatment options, clinicians may hinder patients from making informed decisions. METHODS: From 2017 to 2019, we conducted a mixed-methods study. First, we elicited clinicians' (n = 13 medical, radiation, and surgery clinicians), patients' (n = 18), and caregivers' (n = 14) perceptions of information needed for decision making regarding preoperative therapy and generated a list of key elements. Next, we audio-recorded patients' (n = 20) initial multidisciplinary oncology visits and used qualitative content analyses to describe how clinicians discussed this information and surveyed patients to ask if they heard each key element. RESULTS: We identified 13 key elements of information patients need when making decisions regarding preoperative therapy, including treatment complications, alternatives, logistics, and potential outcomes. Patients reported hearing infrequently about complications (eg, hospitalizations [n = 3 of 20]) and alternatives (n = 8 of 20) but frequently recalled logistics and potential outcomes (eg, likelihood of surgery [n = 19 of 20]). Clinicians infrequently discussed complications (eg, hospitalizations [n = 7 of 20]), but frequently discussed alternatives, logistics, and potential outcomes (eg, likelihood of surgery [n = 20 of 20]). No overarching differences in clinician discussion content emerged to explain why patients did or did not hear about each key element. CONCLUSION: We identified key elements of information patients with pancreatic cancer need when considering preoperative therapy. Patients infrequently heard about treatment complications and alternatives, while frequently hearing about logistics and potential outcomes, underscoring areas for improvement in educating patients about new treatment options in oncology.
- 1 March 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (3) , e313-e324
Communicating the Information Needed for Treatment Decision Making Among Patients With Pancreatic Cancer Receiving Preoperative Therapy
PURPOSE: Preoperative therapy for pancreatic cancer represents a new treatment option with the potential to improve outcomes for patients, yet with complex risks. By not discussing the potential risks and benefits of new treatment options, clinicians may hinder patients from making informed decisions. METHODS: From 2017 to 2019, we conducted a mixed-methods study. First, we elicited clinicians' (n = 13 medical, radiation, and surgery clinicians), patients' (n = 18), and caregivers' (n = 14) perceptions of information needed for decision making regarding preoperative therapy and generated a list of key elements. Next, we audio-recorded patients' (n = 20) initial multidisciplinary oncology visits and used qualitative content analyses to describe how clinicians discussed this information and surveyed patients to ask if they heard each key element. RESULTS: We identified 13 key elements of information patients need when making decisions regarding preoperative therapy, including treatment complications, alternatives, logistics, and potential outcomes. Patients reported hearing infrequently about complications (eg, hospitalizations [n = 3 of 20]) and alternatives (n = 8 of 20) but frequently recalled logistics and potential outcomes (eg, likelihood of surgery [n = 19 of 20]). Clinicians infrequently discussed complications (eg, hospitalizations [n = 7 of 20]), but frequently discussed alternatives, logistics, and potential outcomes (eg, likelihood of surgery [n = 20 of 20]). No overarching differences in clinician discussion content emerged to explain why patients did or did not hear about each key element. CONCLUSION: We identified key elements of information patients with pancreatic cancer need when considering preoperative therapy. Patients infrequently heard about treatment complications and alternatives, while frequently hearing about logistics and potential outcomes, underscoring areas for improvement in educating patients about new treatment options in oncology.